ARCUTIS BIOTHERAPEUTICS, INC. Other Noncash Income (Expense)
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) reported Other Noncash Income (Expense) of -$491.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OtherNoncashIncomeExpense · last filed 2026-08-05
- ARCUTIS BIOTHERAPEUTICS, INC. other noncash income (expense) for the quarter ending 2026-06-30 was -$277.00K.
- ARCUTIS BIOTHERAPEUTICS, INC. other noncash income (expense) for the quarter ending 2026-03-31 was -$214.00K.
- ARCUTIS BIOTHERAPEUTICS, INC. other noncash income (expense) for the quarter ending 2025-12-31 was -$21.00K.
- ARCUTIS BIOTHERAPEUTICS, INC. other noncash income (expense) for the quarter ending 2025-09-30 was -$283.00K.
- ARCUTIS BIOTHERAPEUTICS, INC. other noncash income (expense) for fiscal 2025 was -$652.00K.
- ARCUTIS BIOTHERAPEUTICS, INC. other noncash income (expense) for fiscal 2024 was -$769.00K.
- ARCUTIS BIOTHERAPEUTICS, INC. other noncash income (expense) for fiscal 2023 was -$1.98M.
| Period end | Other Noncash Income (Expense) 3 month | Other Noncash Income (Expense) 6 month | Other Noncash Income (Expense) 9 month | Other Noncash Income (Expense) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$277.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$491.00K 10-Q · filed 2026-08-05 | -$512.00K derived: sum of 3 quarters · filed 2026-08-05 | -$795.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$214.00K 10-Q · filed 2026-05-06 | -$235.00K derived: sum of 2 quarters · filed 2026-05-06 | -$518.00K derived: sum of 3 quarters · filed 2026-05-06 | -$812.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$21.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$304.00K derived: sum of 2 quarters · filed 2026-02-25 | -$598.00K derived: sum of 3 quarters · filed 2026-08-05 | -$652.00K 10-K · filed 2026-02-25 |
| 2025-09-30 | -$283.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | -$577.00K derived: sum of 2 quarters · filed 2026-08-05 | -$631.00K 10-Q · filed 2025-10-28 | -$1.03M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$294.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$348.00K 10-Q · filed 2026-08-05 | -$750.00K derived: sum of 3 quarters · filed 2026-08-05 | -$1.24M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$54.00K 10-Q · filed 2026-05-06 | -$456.00K derived: sum of 2 quarters · filed 2026-05-06 | -$946.00K derived: sum of 3 quarters · filed 2026-05-06 | |
| 2024-12-31 | -$402.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$892.00K derived: sum of 2 quarters · filed 2026-02-25 | -$769.00K 10-K · filed 2026-02-25 | |
| 2024-09-30 | -$490.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | -$367.00K 10-Q · filed 2025-10-28 | ||
| 2024-06-30 | $123.00K 10-Q · filed 2025-08-06 | |||
| 2023-12-31 | -$1.98M 10-K · filed 2026-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |